Roflumilast in Non-CF Bronchiectasis Study (2019)
Anti-inflammatory Effects of Roflumilast Treatment for 12 Weeks in Stable-state Non-cystic Fibrosis Bronchiectasis
Sponsor: The University of Hong Kong
A PHASE2 clinical study on Non-cystic Fibrosis Bronchiectasis, this trial is completed. The trial is conducted by The University of Hong Kong and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Jan 2025 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Dec 2023 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
May 2021 — Dec 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- The University of Hong Kong
For direct contact, visit the study record on ClinicalTrials.gov .